Tenax Selling General Administrative from 2010 to 2024
| TENX Stock | USD 5.36 0.03 0.56% |
Selling General Administrative | First Reported 1996-09-30 | Previous Quarter 1.3 M | Current Value 1.5 M | Quarterly Volatility 1.2 M |
Check Tenax Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tenax Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 7.2 K, Other Operating Expenses of 8.4 M or Research Development of 3.6 M, as well as many indicators such as Price To Sales Ratio of 141.3 K, Dividend Yield of 3.31 or PTB Ratio of 0.71. Tenax financial statements analysis is a perfect complement when working with Tenax Therapeutics Valuation or Volatility modules.
Tenax | Selling General Administrative |
Latest Tenax Therapeutics' Selling General Administrative Growth Pattern
Below is the plot of the Selling General Administrative of Tenax Therapeutics over the last few years. It is Tenax Therapeutics' Selling General Administrative historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tenax Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Selling General Administrative | 10 Years Trend |
|
Selling General Administrative |
| Timeline |
Tenax Selling General Administrative Regression Statistics
| Arithmetic Mean | 6,739,086 | |
| Geometric Mean | 6,044,465 | |
| Coefficient Of Variation | 47.60 | |
| Mean Deviation | 2,171,325 | |
| Median | 5,678,581 | |
| Standard Deviation | 3,207,477 | |
| Sample Variance | 10.3T | |
| Range | 12.3M | |
| R-Value | (0.24) | |
| Mean Square Error | 10.4T | |
| R-Squared | 0.06 | |
| Significance | 0.38 | |
| Slope | (173,763) | |
| Total Sum of Squares | 144T |
Tenax Selling General Administrative History
About Tenax Therapeutics Financial Statements
Tenax Therapeutics investors use historical fundamental indicators, such as Tenax Therapeutics' Selling General Administrative, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Tenax Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Selling General Administrative | 5 M | 4.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Tenax Stock Analysis
When running Tenax Therapeutics' price analysis, check to measure Tenax Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tenax Therapeutics is operating at the current time. Most of Tenax Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tenax Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tenax Therapeutics' price. Additionally, you may evaluate how the addition of Tenax Therapeutics to your portfolios can decrease your overall portfolio volatility.